ALZHEIMER’S DISEASE

Enrollment Pending for Phase 2 Study

Enrollment is pending for our Phase 2 study to evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease (AD).

Trial initiation received approval in June 2024 from the Australia Human Research Ethics Committee.

FOR OUR UPCOMING CLINICAL TRIAL IN AUSTRALIA:

NCT06427668
Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov

 
Locations
Flinders Medical Center, Adelaide, SA, Australia

Contact: Aimee Cayzer at Flinders Medical Center 
RAPMTU@sa.gov.au

 
St Vincents, Sydney, NSW, Australia

Contact: Bruce Brew, MBBS MD DSc, at St Vincents
b.brew@unsw.edu.au

 

For additional information, visit ClinicalTrials.gov